Regulatory Beat: FDA and Industry Seek New Strategies to Curb Counterfeiting and Diversion - A multi-layered approach is needed to authenticate biotech therapies and provide a secure distribution

ADVERTISEMENT

Regulatory Beat: FDA and Industry Seek New Strategies to Curb Counterfeiting and Diversion
A multi-layered approach is needed to authenticate biotech therapies and provide a secure distribution chain


BioPharm International
Volume 19, Issue 4


Jill Wechsler
FDA has to decide by the end of the year whether to implement a rule to track a drug's pathway from manufacturer to final dispenser, even if it means starting with an outmoded, paper-based pedigree system. The policy aims to thwart drug counterfeiting, which is on the rise around the world. This poses a serious threat to public health, particularly when injectable drugs are involved. While FDA has delayed action, states and major retailers are responding by implementing their own drug pedigree requirements. Manufacturers are testing authentication and tracking systems. So far, most solutions appear costly, but may be valuable in modernizing inventory and distribution systems and avoiding legal and regulatory problems.

PUSH FOR RFID

FDA held a public workshop in early February to examine the progress made over the last two years in implementing electronic track-and-trace technologies, based on a radio frequency identification system (RFID). This initiative arose from the Prescription Drug Marketing Act of 1987 (PDMA), which aimed to combat drug counterfeiting by requiring "unauthorized wholesalers" to provide purchasers with a statement (a.k.a. pedigree) presenting a history of prior sales of the drug and the names and addresses of parties to these transactions. The legislation also required states to license wholesale drug distributors and curbed drug sampling. Those provisions were implemented years ago, but industry convinced FDA that a paper pedigree system would be costly and cumbersome. FDA agreed to delay implementation until manufacturers, distributors, and pharmacists could develop a workable approach.

By 2004, the solution appeared to lie in an RFID tracking system. An FDA Counterfeit Drug Task Force issued a report that reviewed recent technological and policy developments and concluded that the agency should postpone the pedigree requirement once more to provide time to implement an electronic tracking system by 2007.




But participants at this year's workshop acknowledged that implementation of a workable tracking system based on RFID still is years away. The Biotechnology Industry Organization (BIO) pointed to technological limitations, a lack of uniform standards, and concerns about the effect of RFID tags on biological stability for slowing RFID adoption. Progress has been "disappointing," commented FDA deputy commissioner Scott Gottlieb last month at a drug anti-counterfeiting forum sponsored by FDA. He noted a lack of agreement on key issues, such as who pays for RFID and who owns transaction data. FDA's task force is scheduled to report back in May on whether to delay the pedigree rule once more or to implement the requirement, possibly with some changes.

DIVERGENT VIEWPOINTS

One problem is that manufacturers, wholesalers, and pharmacists disagree on how best to address these issues. Drug and biotech companies want FDA to implement the pedigree policy as a way to pressure all parties to move forward, while leaving the door open to the development of tracking technologies besides RFID.

Wholesalers and retail pharmacists insist that any national drug pedigree system has to be electronic. Distributors want FDA to phase in an RFID system utilizing electronic product codes (EPC), allowing enough time to develop needed data management and sharing processes. The National Association of Chain Drug Stores would like the agency to clarify that pedigrees apply only to parties outside the "normal distribution chain."

FDA and industry are under pressure to act as a growing number of states adopt their own drug pedigree requirements. Florida enacted a law in 2003 to discourage drug counterfeiting and diversion by requiring wholesalers to provide paper pedigrees for prescription drugs; it becomes fully effective in July 2006. California expects to implement a drug pedigree policy in 2007 or 2008 that establishes an electronic tracking system able to transmit extensive product data on all drugs.

Members of Congress also are introducing legislation establishing a time frame for phasing in electronic tracking of prescription drugs. One bill requires RFID tracking of the 30 most frequently counterfeited drugs (to be determined by FDA) by December 31, 2007. Another goes even further in requiring paper pedigrees until RFID technology is fully established.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here